Abstract:Summary Background People living with HIV (PLWH) with multidrug-resistant (MDR) viruses have limited therapeutic options and present challenges regarding clinical management. Recent studies have shown that passive transfer of combination broadly neutralizing antibodies (bNAbs) against HIV and anti-domain 1 CD4 antibody UB-421 can sustain virologic suppression in PLWH in the absence of antiretroviral therapy (ART). Yet studies addressing the therapeutic potential of these antibodies and/or detailed characterization of immunologic and virologic parameters in PLWH with MDR HIV are lacking. Methods We examined levels of immune activation and exhaustion markers on CD8 + T cells and the intact HIV proviral DNA burden in 11 PLWH with MDR viruses. For comparison purposes, we included a control group consisting of 27 ART-naïve viremic PLWH. In addition, we determined the sensitivity of infectious viral isolates obtained from the participants against eight bNAbs (3BNC117, 10-1074, VRC01, VRC07, N6, 10E8, PGDM1400, and PGT121) and two anti-CD4 antibodies (ibalizumab and UB-421) using a TZM-bl-based neutralization/suppression assay. Findings The level of intact HIV proviral DNA was comparable between the two groups ( P = 0.29). The levels of activation and exhaustion markers PD-1 ( P = 0.0019), TIGIT ( P = 0.0222), 2B4 ( P = 0.0015), CD160 ( P = 0.0015), and CD38 + /HLA-DR + ( P = 0.0138) were significantly lower in the MDR group. The infectious viral isolates from each study participant with MDR HIV were resistant to at least 2 bNAbs; however, they were sensitive to at least one of the CD4-binding and non-CD4-binding site antibodies. The majority of participants had ibalizumab-sensitive viruses although the isolates from some participants showed reduced sensitivity to ibalizumab. Notably, none of the 93 viral isolates obtained from the participants were resistant to UB-421. Interpretation Our data suggest that combination therapy with HIV-specific bNAbs and/or UB-421 in the presence of optimized background therapy could potentially provide sustained virologic suppression in PLWH with MDR HIV. However, this therapeutic strategy needs to be evaluated in human clinical trials. Funding Division of Intramural Research , National Institute of Allergy and Infectious Diseases, National Institutes of Health .

Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A

Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro

No Antagonism or Cross-Resistance and a High Barrier to the Emergence of Resistance in Vitro for the Combination of Islatravir and Lenacapavir.

Knocking-Out Concentrations of HIV-1-Specific Inhibitors Completely Suppress HIV-1 Infection and Prevent the Emergence of Drug-Resistant Virus

A novel preventive strategy against HIV-1 infection: combinatorial use of inhibitors targeting the nucleocapsid and fusion proteins

Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection

Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains

Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs.

A novel preventive strategy against HIV-1 infection: combinatorial use of inhibitors targeting the nucleocapsid and fusion proteins <subtitle>Combination of SAMT10 and SFT against HIV-1</subtitle>

Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis

Anti-HIV Antibody and Drug Combinations Exhibit Synergistic Activity Against Drug-Resistant HIV-1 Strains

Combination anti-HIV antibodies provide sustained virological suppression

Two-drug regimens for HIV treatment

The Anti-Hiv Activity of Three 2-Alkylsulfanyl-6-benzyl-3, 4-Dihydropyrimidin-4 (3H)-One Derivatives Acting As Non-Nucleoside Reverse Transcriptase Inhibitor in Vitro.

Simultaneously Inhibition of Hiv and Hbv Replication Through A Dual Small Interfering Rna Expression System

Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV

Meta-analysis and Systematic Review of the Efficacy and Resistance for Human Immunodeficiency Virus Type 1 Integrase Strand Transfer Inhibitors.

Combination and Monotherapy with Zidovudine and Zalcitabine in Patients with Advanced HIV Disease

A Comprehensive Analysis of HIV Treatment Efficacy in the ACTG 175 Trial Through Multiple-Endpoint Approaches

Suppression of Active HIV-1 Infection in CD34+ Hematopoietic Humanized NSG Mice by a Combination of Combined Antiretroviral Therapy and CCR5 Targeting Drugs

Combinations of the First and Next Generations of Human Immunodeficiency Virus (HIV) Fusion Inhibitors Exhibit a Highly Potent Synergistic Effect Against Enfuvirtide- Sensitive and -Resistant HIV Type 1 Strains